Looking at the filing, I need to identify key financial data. The filing text includes the cover page and table of contents but the actual financial statements (balance sheets, income statements) are referenced but not fully reproduced in the extracted text. I'll work with what is available.

Progyny, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 7, 2026, covering the quarterly period ended June 30, 2026.

Key Highlights

  • Shares outstanding: As of July 31, 2026, Progyny had 76,726,798 shares of common stock, $0.0001 par value per share, outstanding.
  • Exchange listing: The common stock trades on The Nasdaq Global Select Market under the symbol PGNY.
  • Filer status: The company is classified as a large accelerated filer, not a smaller reporting company or emerging growth company.
  • Filing period: The report covers the three and six months ended June 30, 2026, with comparative periods ended June 30, 2025.
  • Forward-looking statements: The filing contains forward-looking statements subject to the company's cautionary language, including risks related to competition, economic conditions, and evolving laws on reproductive rights.

Progyny's Second-Quarter 2026 Quarterly Disclosure: Filing Details and Risk Overview

Progyny, Inc. (NASDAQ: PGNY), a fertility benefits management company headquartered at 1359 Broadway, New York, New York 10018, filed its Form 10-Q for the quarterly period ended June 30, 2026. According to the filing, the company confirmed it had filed all reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and had submitted all required Interactive Data Files electronically.

The filing includes consolidated financial statements covering the three and six months ended June 30, 2026 and 2025, along with management's discussion and analysis, quantitative and qualitative disclosures about market risk, and controls and procedures disclosures. The report also includes an updated risk factors section under Part II, Item 1A, which the company states should be read alongside the management's discussion and analysis section.

Among the principal risk factors summarized in the filing, the company identified potential failure to meet publicly announced guidance, competitive market conditions, and unfavorable global economic conditions as factors that could harm its business, financial condition, and results of operations. The filing also notes the potential impact of "evolving laws and regulations, including any laws and regulations restricting reproductive rights" as a forward-looking risk, described in the company's own cautionary language as subject to known and unknown risks and uncertainties.

What Was Disclosed

Progyny filed its Form 10-Q for the period ended June 30, 2026, reporting 76,726,798 shares outstanding as of July 31, 2026, confirming its large accelerated filer status, and outlining key operational and regulatory risk factors facing the business.